Methotrexate and TNF inhibitors affect long-term immunogenicity to COVID-19 vaccination in patients with immune-mediated inflammatory disease
Lancet Rheumatol
.
2022 Jun;4(6):e384-e387.
doi: 10.1016/S2665-9913(22)00069-8.
Epub 2022 Apr 1.
Authors
Rebecca H Haberman
1
,
Seungha Um
2
,
Jordan E Axelrad
3
,
Rebecca B Blank
1
,
Zakwan Uddin
1
,
Sydney Catron
1
3
,
Andrea L Neimann
4
,
Mark J Mulligan
5
6
,
Ramin Sedaghat Herat
5
6
,
Simon J Hong
3
,
Shannon Chang
1
3
,
Arnold Myrtaj
3
,
Ghoncheh Ghiasian
3
,
Peter M Izmirly
1
,
Amit Saxena
1
,
Gary Solomon
1
,
Natalie Azar
1
,
Jonathan Samuels
1
,
Brian D Golden
1
,
Paula Rackoff
1
,
Samrachana Adhikari
2
,
David P Hudesman
3
,
Jose U Scher
1
;
SAGA investigators
Affiliations
1
Division of Rheumatology, Department of Medicine, NYU Grossman School of Medicine, New York, NY 10016, USA.
2
Department of Population Health, New York University Langone Health, New York, NY, USA.
3
Division of Gastroenterology, Department of Medicine, NYU Grossman School of Medicine, New York, NY 10016, USA.
4
Department of Dermatology, New York University Langone Health, New York, NY, USA.
5
Division of Infectious Disease, Department of Medicine, NYU Grossman School of Medicine, New York, NY 10016, USA.
6
Vaccine Center, Department of Medicine, NYU Grossman School of Medicine, New York, NY 10016, USA.
PMID:
35403000
PMCID:
PMC8975261
DOI:
10.1016/S2665-9913(22)00069-8
No abstract available
Grants and funding
K23 DK124570/DK/NIDDK NIH HHS/United States